All patients
adolescents (typically 12-15 years of age) adults (typically between 18 and 65yr) age >= 55 yr age >= 60 yr age >= 65 yr age >= 75 yr alpha variant (B.1.1.7, UK) any cancer autoimmune disease beta variant (B.1.351 / 501Y.V2, South Africa) children corticosteroids: no corticosteroids: yes critical disease delta variant (B.1.617.2, Indian) dialysis patients elderly (typically over 65yr) fully vaccinated gamma variant (P.1, Brazil) haematological cancers healthcare workers immunodepression invasive ventilation kidney transplant recipients no oxygen needed non invasive oxygen obese omicron variant BA.1 (B.1.1.529) omicron variant BA.2 VOC original (Wuhan) strain positive for SARS-Cov-2 at baseline severe disease solid cancer solid organ transplant recipients subjects at risk
potential COVID-19 treatments in COVID-19 severe or critically - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias death D28detailed results CORIMUNO-TOCI-ICU (Group 2), 2020 0.64 [0.23; 1.80]
COVACTA (Rosas), 2020 1.02 [0.62; 1.68]
MARIPOSA, 2021 1.43 [0.42; 4.87]
Rosas (REMDACTA), 2021 0.95 [0.65; 1.39]
Talaschian, 2021 1.56 [0.34; 7.13]
Veiga, 2021 2.70 [0.92; 7.92]
1.04 [0.80 ; 1.37 ] CORIMUNO-TOCI-ICU (Group 2), 2020, COVACTA (Rosas), 2020, MARIPOSA, 2021, Rosas (REMDACTA), 2021, Talaschian, 2021, Veiga, 2021 6 0% 1,432 moderate not evaluable deathsdetailed results CORIMUNO-TOCI-1 (Group 1), 2020 0.92 [0.31; 2.71]
CORIMUNO-TOCI-ICU (Group 2), 2020 0.64 [0.23; 1.80]
COVACTA (Rosas), 2020 1.16 [0.73; 1.84]
Lescure (Sarilumab 200mg), 2021 1.23 [0.49; 3.12]
Lescure (Sarilumab 400mg), 2021 0.97 [0.38; 2.50]
REMAP-CAP (tocilizumab), 2021 0.70 [0.51; 0.95]
Rosas (REMDACTA), 2021 0.95 [0.65; 1.39]
Talaschian, 2021 1.25 [0.30; 5.14]
Veiga, 2021 2.70 [0.92; 7.92]
0.93 [0.75 ; 1.15 ] CORIMUNO-TOCI-1 (Group 1), 2020, CORIMUNO-TOCI-ICU (Group 2), 2020, COVACTA (Rosas), 2020, Lescure (Sarilumab 200mg), 2021, Lescure (Sarilumab 400mg), 2021, REMAP-CAP (tocilizumab), 2021, Rosas (REMDACTA), 2021, Talaschian, 2021, Veiga, 2021 9 10% 2,730 moderate not evaluable deaths (time to event analysis only)detailed results COVACTA (Rosas), 2020 1.16 [0.73; 1.84]
Rosas (REMDACTA), 2021 0.95 [0.65; 1.39]
Talaschian, 2021 1.25 [0.30; 5.14]
1.04 [0.78 ; 1.38 ] COVACTA (Rosas), 2020, Rosas (REMDACTA), 2021, Talaschian, 2021 3 0% 1,132 moderate not evaluable clinical deteriorationdetailed results CORIMUNO-TOCI-1 (Group 1), 2020 0.56 [0.26; 1.20]
0.56 [0.26 ; 1.20 ] CORIMUNO-TOCI-1 (Group 1), 2020 1 0% 130 NA not evaluable clinical improvementdetailed results COVACTA (Rosas), 2020 1.19 [0.81; 1.75]
Lescure (Sarilumab 200mg), 2021 1.03 [0.75; 1.41]
REMAP-CAP (tocilizumab), 2021 1.64 [1.25; 2.15]
1.28 [0.95 ; 1.72 ] COVACTA (Rosas), 2020, Lescure (Sarilumab 200mg), 2021, REMAP-CAP (tocilizumab), 2021 3 62% 1,440 moderate not evaluable clinical improvement (28-day)detailed results COVACTA (Rosas), 2020 1.19 [0.81; 1.75]
1.19 [0.81 ; 1.75 ] COVACTA (Rosas), 2020 1 0% 438 NA not evaluable clinical improvement (time to event analysis only)detailed results Lescure (Sarilumab 200mg), 2021 1.03 [0.75; 1.41]
Lescure (Sarilumab 400mg), 2021 1.14 [0.84; 1.54]
1.09 [0.87 ; 1.35 ] Lescure (Sarilumab 200mg), 2021, Lescure (Sarilumab 400mg), 2021 2 0% 506 moderate not evaluable death or ventilationdetailed results CORIMUNO-TOCI-1 (Group 1), 2020 0.56 [0.24; 1.31]
Rosas (REMDACTA), 2021 0.98 [0.72; 1.34]
Veiga, 2021 1.54 [0.65; 3.63]
0.96 [0.65 ; 1.43 ] CORIMUNO-TOCI-1 (Group 1), 2020, Rosas (REMDACTA), 2021, Veiga, 2021 3 26% 909 moderate not evaluable hospital dischargedetailed results MARIPOSA, 2021 0.88 [0.55; 1.40]
Rosas (REMDACTA), 2021 0.97 [0.79; 1.20]
0.95 [0.79 ; 1.16 ] MARIPOSA, 2021, Rosas (REMDACTA), 2021 2 0% 649 moderate not evaluable mechanical ventilationdetailed results COVACTA (Rosas), 2020 0.67 [0.39; 1.14]
MARIPOSA, 2021 0.88 [0.37; 2.10]
0.72 [0.46 ; 1.14 ] COVACTA (Rosas), 2020, MARIPOSA, 2021 2 0% 370 moderate not evaluable ICU admissiondetailed results COVACTA (Rosas), 2020 0.48 [0.25; 0.94]
0.48 [0.25 ; 0.94 ] COVACTA (Rosas), 2020 1 0% 191 NA not evaluable recoverydetailed results Talaschian, 2021 0.64 [0.14; 2.92]
0.64 [0.14 ; 2.92 ] Talaschian, 2021 1 0% 36 NA not evaluable serious adverse eventsdetailed results COVACTA (Rosas), 2020 0.81 [0.54; 1.22]
Lescure (Sarilumab 200mg), 2021 1.15 [0.62; 2.12]
Lescure (Sarilumab 400mg), 2021 1.38 [0.76; 2.51]
Rosas (REMDACTA), 2021 0.83 [0.59; 1.18]
Talaschian, 2021 7.93 [0.37; 171.38]
Veiga, 2021 1.66 [0.60; 4.59]
0.99 [0.77 ; 1.28 ] COVACTA (Rosas), 2020, Lescure (Sarilumab 200mg), 2021, Lescure (Sarilumab 400mg), 2021, Rosas (REMDACTA), 2021, Talaschian, 2021, Veiga, 2021 6 16% 1,747 moderate serious adverse eventsdetailed results COVACTA (Rosas), 2020 0.87 [0.52; 1.45]
Lescure (Sarilumab 200mg), 2021 0.97 [0.56; 1.69]
Lescure (Sarilumab 400mg), 2021 1.31 [0.76; 2.27]
Rosas (REMDACTA), 2021 1.32 [0.92; 1.89]
Veiga, 2021 1.65 [0.81; 3.37]
1.18 [0.95 ; 1.48 ] COVACTA (Rosas), 2020, Lescure (Sarilumab 200mg), 2021, Lescure (Sarilumab 400mg), 2021, Rosas (REMDACTA), 2021, Veiga, 2021 5 0% 1,711 moderate not evaluable 0.2 2.0 1.0 relative treatment effect www.metaEvidence.org 2024-10-02 06:04 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 91
- treatments: 290,547,608,830,831,829,901,680,595,828,681,1209,833,629,689,543,617,625,859,511,960,546,564,944,682,1266,943,894,560,1102,598,563,668,753,752,836,639,541,534,581,615,679,522,582,666,1149,1150,737,544,733,597,524,611,538,957,958,521,566,517,881,904,882,897,896,899,1235,898,687,740,883,947,536,591,729,887,742,878,975,570,771,888,1141,690,880,1255,567,596,1437,600,652,557,635,1236,553,628,646,645,607,395,920,1438,927,932,931,1263,599,614,942,1436,928,923,535,1046,727,818,606,954,964,962,963,1045,638,677,627,533,526,616,926,1246,726,580,568,527,588,539,585,691,1210,525,843,827,1047,1048,819,545,1253,519,619,537,514,688,529,508,656,657,832,530,512,515,754,1142,1419,513,884,632,559,889,956,684,886,631,574,509,542,1145,555,554,941,961,1250,633,676,518,532,510,528,520,955,815,893,623,622,630,593,569,516,814,649,650,589,651,968,1245,610,751,747,695,548,970,594,565,879,1257,571,626,697,572,1234,586,573,540,592,930,949,838,698,934,735,929,948,946,945,587,655,1146,531,933,613,919,725,678,921,621,959,748,1348,1256,924,1243,925,658,699,612,552,590,891,605,892,722,618,609,551,834,763,922,935,620,1317,1265,824,766,857,1291,1088,1331,1330,1329,1344,1328,1327,979,822,762,805,950,757,761,806,758,826,755,821,1288,1287,1286,760,1284,802,765,1285,759,823,804,1264,764,858,835,1262,1290,1316,1341,1342,1343,825,803,1244,523,885,734,1439
- roots T: 290